Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    20951424 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Completed A Study of Combination Treatment With an HCV Polymerase Inhibitor (RO5024048) and an HCV Protease Inhibitor (RO5190591/Danoprevir) in Genotype 1 Chronic Hepatitis C Patients
Condition: Hepatitis C, Chronic
Interventions: Drug: RO5024048;   Drug: danoprevir

Indicates status has not been verified in more than two years